← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	2,460	-119	-5%	$135B
2	2 Danaher DHR $158B	2,176	-50	-2%	$114B
3	3 Novartis NVS $279B	1,386	+27	+2%	$16.2B
4	4 Regeneron Pharmaceuticals REGN $80.1B	1,203	-90	-7%	$46.9B
5	5 Agilent Technologies A $49.1B	1,010	-14	-1%	$30B
6	6 Illumina ILMN $41B	739	+16	+2%	$14.8B
7	7 Alnylam Pharmaceuticals ALNY $30B	655	+27	+4%	$43.1B
8	8 Revvity RVTY $17B	540	+8	+2%	$11.1B
9	9 Charles River Laboratories CRL $14.4B	519	-42	-7%	$7.73B
10	10 CRISPR Therapeutics CRSP $4.86B	434	+37	+9%	$3.52B
11	11 Bruker BRKR $8.47B	370	-29	-7%	$5.12B
12	12 Guardant Health GH $21.9B	365	+23	+7%	$6.47B
13	13 Sarepta Therapeutics SRPT $1.78B	363	-68	-16%	$1.42B
14	14 Ionis Pharmaceuticals IONS $7.1B	362	+18	+5%	$6.67B
15	15 BridgeBio Pharma BBIO $12.7B	359	+55	+18%	$8.15B
16	16 GRAIL Inc GRAL $6.24B	344	+30	+10%	$1.35B
17	17 Qiagen QGEN $9.41B	319	+19	+6%	$7.23B
18	18 Ultragenyx Pharmaceutical RARE $1.47B	310	+10	+3%	$3.42B
19	19 10x Genomics TXG $9.52B	297	+23	+8%	$1.42B
20	20 PTC Therapeutics PTCT $4.98B	284	+23	+9%	$3.9B
21	21 Arrowhead Research ARWR $8.25B	282	+17	+6%	$1.67B
22	22 Intellia Therapeutics NTLA $1.6B	282	-14	-5%	$934M
23	23 Azenta AZTA $1.63B	278	-16	-5%	$1.64B
24	24 Veracyte VCYT $3.5B	278	-9	-3%	$2.31B
25	25 Krystal Biotech KRYS $9.79B	275	-24	-8%	$3.8B